quote:Originally posted by Machiavelli: this one gapped up too high ... it has nowhere to go now but down for a massive "correction" ... think about taking your profits peeps... you can always buy back in later on... <shrugs> i could be wrong though... just don't get too greedy.. MM's will short it sooner or later...
^^^ 6.33 6.00 in aftermarket ^^^
-------------------- Let the world change you... And you can change the world.
Ernesto "Che" Guevara de la Serna Posts: 4669 | Registered: Mar 2004
| IP: Logged |
posted
Didn't it go up about 50% after you said "It has no where to go but down"?
I know you've been here a long time and respect you and all the advice that you give to everyone, but what was the point of your post there? It seems like you didn't go out on much of a limb by saying a stock that was up 200% was due to pull back. Just seems out of character for someone that I've always thought was very helpful to others to make an "I told you so" post.
quote:Originally posted by Machiavelli:
quote:Originally posted by Machiavelli:
quote:Originally posted by Machiavelli: this one gapped up too high ... it has nowhere to go now but down for a massive "correction" ... think about taking your profits peeps... you can always buy back in later on... <shrugs> i could be wrong though... just don't get too greedy.. MM's will short it sooner or later...
^^^ 6.33 6.00 in aftermarket ^^^
Posts: 5508 | From: Southeastern PA | Registered: Jan 2006
| IP: Logged |
posted
I made a warning on this one just like i did with QBID... people like to take my advice on how to get into trading but not so much so when I make a analysis of a stock... this post wasnt so much a "I told you so" post.. but more like a lesson post... Don't fall in love with a stock... learn to let it go if need be... more fish in the sea... but if it bothered you... I won't make any more analysis posts... some people need to learn from experience... I don't mean you in particular... just in general...
-------------------- Let the world change you... And you can change the world.
Ernesto "Che" Guevara de la Serna Posts: 4669 | Registered: Mar 2004
| IP: Logged |
posted
Ok, could just be the way intent is often lost on message board postings. I just read it as an "I told you so" given the eye rolling. Entirely possible that I was the only one to interpet it that way.
Tex, it would be only slightly hypocritical if I got upset at someone for pointing out the downside of a stock. That was not my point. Just the way it came across to me seemed more hurtful than helpful.
Anyway, Mach, I'm obviously not suggesting you cease posting your analysis, and am not even suggesting you change the way you word it, was really just asking for clarification0 because of the way that it read to me. As I tried to make clear, it seemed out of character, so I figured it wasn't intended that way.
By the way, I never owned any of this stock, so this was not a case of a holder being overly sensitive to criticism, it was from a neutral observer.
quote:Originally posted by Machiavelli: I made a warning on this one just like i did with QBID... people like to take my advice on how to get into trading but not so much so when I make a analysis of a stock... this post wasnt so much a "I told you so" post.. but more like a lesson post... Don't fall in love with a stock... learn to let it go if need be... more fish in the sea... but if it bothered you... I won't make any more analysis posts... some people need to learn from experience... I don't mean you in particular... just in general...
Posts: 5508 | From: Southeastern PA | Registered: Jan 2006
| IP: Logged |
posted
Don't they still have a chance at approval, they just need to submit more data. I missed the first big gainer, I'm wondering if they eventually do get approval if we'll see a repeat in gains?
-------------------- YOU CAN'T LOSE IF YOU DON'T PLAY, BUT YOU CERTAINLY WON'T WIN!! Posts: 71 | From: Nashville, Tn | Registered: Apr 2007
| IP: Logged |
quote:Originally posted by Stock_Pupil: Don't they still have a chance at approval, they just need to submit more data. I missed the first big gainer, I'm wondering if they eventually do get approval if we'll see a repeat in gains?
They do have a chance still, but the only thing that took this stock from $4 PPS was the hopes of approval NOW. Without approval, it goes back to its pre-hyped price until it gets close the approval again. So IF there is approval, yes, will see a repeat in gains.
Posts: 869 | From: Az | Registered: Sep 2006
| IP: Logged |
posted
till it gets approval it will stay down unless rumors of it's pending approval starts driving the stock up again... the MM's will go long... but in all fairness I hope it does get approved because I lost someone due to cancer recently so in the case of this company I really don't care about trading but care more about saving lives...
-------------------- Let the world change you... And you can change the world.
Ernesto "Che" Guevara de la Serna Posts: 4669 | Registered: Mar 2004
| IP: Logged |
posted
Dendreon Slashes 40 Jobs, Or 18% Of Work Force >
DNDN Last update: 5/21/2007 7:11:38 AM
DOW JONES NEWSWIRES
Dendreon Corp.'s (DNDN) board has approved the elimination of 40 jobs, or 18% of the company work force, in connection with the near-term commercialization of prostate cancer drug Provenge, according to a Securities and Exchange Commission filing Monday.
As reported earlier this month, the Seattle biotechnology company lost more than half its market capitalization and most of its stock gains since March after the Food and Drug Administration requested more clinical data supporting the drug's effectiveness.
The FDA made the request in an "approvable letter," meaning the agency is prepared to approve the medicine if certain conditions are met.
Dendreon didn't say how long the request for more data will delay Provenge's arrival on the market. Following the job cuts, the company will have about 200 employees remaining at facilities in Seattle and Morris Plains, N.J.
According to Monday's SEC filing, Dendreon expects to incur non-cash charges of up to $300,000 and cash charges of up to $1.5 million associated with the work force reduction. The company's shares closed Friday at $6.07.
-Chad Clinton, Dow Jones Newswires; 202-862-1349; chad.clinton*dowjones.com (END) Dow Jones Newswires
-------------------- "Great Day for Up!"....Dr. Seuss Posts: 3387 | Registered: Mar 2006
| IP: Logged |
posted
Short sellers bet Dendreon's drug won't win FDA approval By Luke Timmerman
Bloomberg News
Dendreon shares are being sold short at a record pace as some investors bet the company's experimental prostate cancer drug will fail to win approval from U.S. regulators.
About 44 percent of Dendreon shares in mid-April were borrowed stock sold short, in anticipation of being replaced at a lower price, according to Nasdaq Stock Market data compiled by Bloomberg. That's a big bet against a stock that has tripled since March 29, when advisers to the Food and Drug Administration (FDA) recommended the medicine.
The drug, called Provenge, is the first of a new class designed to trigger the body's immune system to attack tumors. While Provenge prolonged lives of patients with advanced prostate cancer in one study presented to the panel, the drug didn't meet the trial's primary goal of slowing the spread of the disease.
"Some people are assuming the FDA won't listen to the panel" because of the discrepancy in the study findings, said David Miller, president of Biotech Stock Research, an independent equity research firm in Seattle.
The short-selling is up 28 percent from mid-March and double the amount in January. It's the second-biggest increase on the Nasdaq this month, after ON Semiconductor, a maker of computer chips in Phoenix.
Shares of Seattle-based Dendreon closed down 30 cents, or 1.9 percent, at $15.15 Friday. The shares have almost quadrupled since Jan. 1, the best performance in the Nasdaq biotechnology index.
Dendreon says it expects to hear May 15 whether Provenge will be released for use in the U.S. The company didn't respond to requests for comment on short-selling of the stock.
The FDA, while usually following the advice of advisory panels of scientists and doctors, isn't required by law to do so. Short sellers say the FDA may counter the advisers' ruling and hold off approving Provenge until results come in from another company-sponsored study. Dendreon has said that trial, measuring survival of 500 men with advanced prostate cancer, could take until 2010 to produce results.
"The short data says to me that people do not believe the panel's decision will be mirrored by the FDA," said Jonathan Aschoff, an analyst with Brean Murray Carret & Co. in New York, in a telephone interview. He has rated Dendreon shares "sell" since November 2004 and doesn't own any.
The stock's price surge reflects the lack of good treatments for advanced forms of the cancer, which is often lethal once it spreads beyond the prostate. The disease kills 27,000 men in the U.S. a year. Doctors say they often try treating terminal patients with Taxotere, a drug from Paris-based Sanofi-Aventis. That medicine has side effects and limited usefulness.
Provenge will be Dendreon's first product and may generate $1 billion a year in sales if approved by the FDA. Dendreon, founded in 1992, is trying to be the first drug maker to market a new class of experimental medicines scientists are developing that stimulate the body's immune system to attack cancer.
The company began its final-stage study in prostate cancer patients in 2000. Its only other product in clinical development is an immune-stimulator against breast cancer. Dendreon had an accumulated deficit of $392 million through the end of 2006, according to its annual report.
Short-sellers may be betting that the FDA won't go along with the panel because of the conflicting clinical trial results. Dendreon's own statistical consultant told the advisory panel on March 29 that the research data is "less than perfect."
Dendreon's first trial of 127 men showed that patients on Provenge lived a median 25.9 months, compared with 21.4 months for those on a placebo. A second trial of 98 men showed a median survival of 19 months, compared with 15.7 months for those taking a placebo. That finding wasn't valid because it didn't reach a statistical threshold, the company said.
Both studies failed to demonstrate the drug slowed the cancer's spread, which was their primary goal. Dendreon says the measurement of whether Provenge was slowing the cancer's progress may have been carried out too early in the studies to detect the drug's ability to generate an attack by the immune system.
Dendreon supporters say the chances of Provenge winning approval are good, given limited treatment options for the disease. The FDA can require additional trials after the drug goes to market if it wants more evidence it works, said Charles Duncan, an analyst with JMP Securities in New York, in a note to clients Tuesday.
The first three of the 17 FDA panelists who were polled voted against recommending approval. The entire panel later voted 13-4 to recommend approval after the definition of the drug's effectiveness was changed by FDA staffers who analyzed the drug studies.
William Ho, an analyst with Bank of America Securities in New York, told clients in a Tuesday that he expects FDA approval. He said the staff's revised definition of the drug's effectiveness was designed to "lower the bar" in evaluating Provenge.
Posts: 6 | Registered: May 2007
| IP: Logged |
quote:Originally posted by Stock_Pupil: Hey guys, what's the reason for the recent jump in price on this one, OPTIONS?? I thought it was dead until they improved on some things.
posted May 31, 2007 09:09 -------------------------------------------------------------------------------- flying
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Roll Eyes]](rolleyes.gif)
![[Cool]](cool.gif)
